Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ: CORT )

72.93 +0.21 (+0.29%)
Streaming Delayed Price Updated: 11:07 AM EST, Feb 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via Business Wire
Looking for growth without the hefty price tag? Consider NASDAQ:CORT.
CORCEPT THERAPEUTICS INC could be undervalued. NASDAQ:CORT is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced. 
Via Chartmill
Exploring NASDAQ:CORT's high growth characteristics.
Is CORCEPT THERAPEUTICS INC (NASDAQ:CORT) suited for high growth investing? 
Via Chartmill
Exploring the Growth Potential of NASDAQ:CORT as It Nears a Breakout.
CORCEPT THERAPEUTICS INC (NASDAQ:CORT), a strong growth stock, setting up for a breakout. 
Via Chartmill
NASDAQ:CORT is not too expensive for the growth it is showing.
For those who appreciate growth without the sticker shock, NASDAQ:CORT is worth considering. 
Via Chartmill
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Exploring high growth characteristics of CORCEPT THERAPEUTICS INC (NASDAQ:CORT).
Exploring high growth characteristics of CORCEPT THERAPEUTICS INC (NASDAQ:CORT). 
Via Chartmill
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism
From Corcept Therapeutics Incorporated
Via Business Wire
Investors should take note of NASDAQ:CORT, a growth stock that remains attractively priced.
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism
From Corcept Therapeutics Incorporated
Via Business Wire
Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes
Corcept Therapeutics reports positive Phase 4 CATALYST results, showing Korlym significantly improves hemoglobin A1c in hypercortisolism patients. 
Via Benzinga
NASDAQ:CORT, a strong growth stock, setting up for a breakout.
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) qualifies as a high growth stock and is consolidating. 
Via Chartmill
In the world of growth stocks, NASDAQ:CORT shines as a value proposition.
Looking for growth without the hefty price tag? Consider NASDAQ:CORT. 
Via Chartmill
Earnings Preview: Corcept Therapeutics
Via Benzinga
Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes
From Corcept Therapeutics Incorporated
Via Business Wire
Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)
From Corcept Therapeutics Incorporated
Via Business Wire
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating
NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95. 
Via Investor's Business Daily
For those who appreciate growth without the sticker shock, NASDAQ:CORT is worth considering.
NASDAQ:CORT is showing decent growth, but is still valued reasonably. 
Via Chartmill
Key Takeaways From Corcept Therapeutics Analyst Ratings
Via Benzinga
Is NASDAQ:CORT suited for high growth investing?
Should you consider CORCEPT THERAPEUTICS INC (NASDAQ:CORT) for high growth investing? 
Via Chartmill
NASDAQ:CORT: a strong growth stock preparing for the next leg up?.
Is CORCEPT THERAPEUTICS INC (NASDAQ:CORT) on the Verge of a Major Breakout as a Strong Growth Stock? 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via Business Wire
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via Business Wire
Investors seeking growth at a reasonable cost should explore NASDAQ:CORT.
NASDAQ:CORT is not too expensive for the growth it is showing. 
Via Chartmill
Forecasting The Future: 6 Analyst Projections For Corcept Therapeutics
Via Benzinga
NASDAQ:CORT: a strong growth stock preparing for the next leg up?.
Exploring the Growth Potential of CORCEPT THERAPEUTICS INC (NASDAQ:CORT) as It Nears a Breakout. 
Via Chartmill
Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast
Truist Securities raises the price target for Corcept Therapeutics to $76, driven by robust Korlym sales and promising relacorilant trials. The analyst highlights significant growth potential in the... 
Via Benzinga
NASDAQ:CORT is not too expensive for the growth it is showing.
Investors should take note ofCORCEPT THERAPEUTICS INC (NASDAQ:CORT), a growth stock that remains attractively priced. 
Via Chartmill
For those who appreciate growth without the sticker shock, NASDAQ:CORT is worth considering.
Don't overlook CORCEPT THERAPEUTICS INC (NASDAQ:CORT)—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.